Revenue (GAAP) increased 11.1% to $6.0 billion, above analyst expectations. Adjusted earnings per share rose 11.4% to $3.13, exceeding consensus estimates. Full-year 2025 guidance was raised for both ...

Medical technology company Stryker (NYSE:SYK) reported Q2 CY2025 results topping the market’s revenue expectations, with ...

The medtech firm, which previously forecast a $200 million tariff impact for 2025, also raised its earnings outlook, citing ...

Q2 2025 Management View Kevin A. Lobo, Chair, CEO & President, highlighted, "We delivered double-digit organic sales growth of 10.2% and adjusted EPS growth of 11.4% while managing through the impacts ...

Stryker reached a key milestone with its Mako robotics, Jason Beach, vice president of finance and investor relations, said in a July 31 earnings call. During the second quarter Stryker reached 2 ...

Stryker raised its annual profit forecast and beat quarterly profit estimates on Thursday, banking on strong demand for its medical and surgical devices. Medical and surgical device makers have ...

Stryker sells two product lines, OP-1 and Calstrux, for reconstructing bones damaged by surgery or injury. The products actively recruit new blood supply, promote bone growth, and fill voids in bones.

The Stryker can also be configured in a number of different variants, including some for use by engineers or as ambulances. How will they be used in Ukraine? The Pentagon’s announcement Thursday ...